Information
Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant curre...
Original sourceAI Summary
Illumina's Q4 2025 revenue increased 5% YoY to $1.16 billion, reflecting growth in clinical markets. The company expects 2026 revenues to rise 4%-6%, bolstered by its recent acquisition of SomaLogic. This momentum is fueling confidence as Illumina aims to enhance its genomic testing capabilities and product offerings, making it a key player in precision medicine.
Sentiment Rationale
Strong performance metrics indicate a positive trend, supported by strategic acquisitions and market expansion.
Trading Thesis
Bullish on ILMN as 2026 growth prospects improve with clinical market expansion.
Market-Moving
- Revenue growth of 4%-6% projected for 2026 may boost investor sentiment.
- Successful integration of SomaLogic can enhance product offerings and revenue potential.
- Strong momentum in clinical markets drives confidence ahead of Q1 earnings.
Key Facts
- Q4 2025 revenue of $1.16 billion, up 5% year-over-year.
- Fiscal 2025 total revenue stable at $4.34 billion, flat from 2024.
- 2026 guidance anticipates revenue growth of 4%-6%, aided by SomaLogic.
- Non-GAAP diluted EPS for Q4 2025 increased to $1.35.
- Illumina enters 2026 with strong clinical market momentum.
Companies Mentioned
- SomaLogic (SLGC): Acquisition expected to boost ILMN's multiomics portfolio.
- AstraZeneca (AZN): Partnering on AI-enabled drug discovery enhances Illumina's market relevance.
- Merck (MRK): Involvement in drug discovery boosts potential customer base for ILMN.
- Eli Lilly (LLY): Collaborations may enhance growth potential for genomic applications.
Corporate Developments
This news fits into the 'Corporate Developments' category, highlighting key financial results and strategic acquisitions that directly impact Illumina's market position and future growth prospects within the genomic testing landscape.